Affymax and Takeda Announce Phase 3 Trials Meet Primary Endpoints for ... - MarketWatch (press release) PDF Print
MarketWatch (press release)In a subgroup analysis of CSE events in the EMERALD studies in maintenance treatment of anemia in dialysis patients, the frequency of CSE events was ...Piper Jaffray Downgrades Affymax (AFFY) to Underweight; Disappointing Hematide ... StreetInsider.com (subscription)Affymax shares plunge on PhIII cardio issues for Hematide FierceBiotechAffymax' Anemia Drug Meets Goals Of Phase III Trials; Shares Plunge On Safety

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.